Table 1 Recent patent applications in RNA interference
Patent number | Description | Assignee | Inventor | Priority application date | Publication date |
|---|---|---|---|---|---|
WO 2009103808 | A method for increasing an RNA interference (RNAi) effect of a molecule or composition by contacting the cell(s) or organism with sulfated polysaccharides and/or glycosaminoglycans and an RNAi-inducing molecule. | deVGen (Zwijnaarde, Belgium) | Philips A, Raemaekers R | 2/20/2008 | 8/27/2009 |
WO 2009083738 | A new RNA delivery vehicle comprising a clostridialneurotoxin translocation peptide, useful for delivering an RNA guide strand into a target cell and suppressing or downregulating gene expression by RNAi in a target cell. | Syntaxin (Abingdon, UK) | Beard M, Chaddock J | 12/31/2007 | 7/9/2009, 8/27/2009 |
WO 2009102931,US 20090209627 | A method for treating an intraocular pressure–related condition in an individual comprising administering an interfering RNA molecule that attenuates expression of the connexin 43 (Cx43) mRNA via RNAi. | Alcon Research (Fort Worth, TX, USA) | Chatterton JE, Clark AF, Wax MB | 2/15/2008 | 8/20/2009 |
US 20090192105 | A new chemically modified nucleic acid molecule, useful for modulating intercellular adhesion molecule (ICAM) gene expression, and providing compositions for treating diseases and conditions that respond to ICAM modulation (e.g., cancer). | Sirna Therapeutics (San Francisco) | Beigelman L, McSwiggen J | 2/20/2002 | 7/30/2009 |
US 20090192104 | A new chemically modified nucleic acid molecule, useful for modulating hypoxia inducible factor (HIF), andmodulating expression and activity of other genesinvolved in pathways of HIF1 gene expression and/or activity by RNAi. | Sirna Therapeutics (San Francisco) | Beigelman L, McSwiggen J | 2/20/2002 | 7/30/2009 |
WO 2009088786 | A method of treating heart failure comprisingadministering to an individual a vector comprising an RNAi expression cassette to decrease expression oractivity of phospholamban. | Nanocor Therapeutics (Chapel Hill, NC, USA) | Fechner H, Hajjar RJ, Poller WC | 12/31/2007 | 7/16/2009 |
US 20090181913 | A novel specific 78-kDa glucose-regulated protein (GRP78) expression-inhibition RNAi used for inhibiting growth, metastasis and invasion of cancer cells. | Chang JT, Cheng A, Chiu C | Chang JT, Cheng A, Chiu C | 1/11/2008 | 7/16/2009 |
WO 2009082488 | A method of producing a hairpin DNA moleculecomprising a loop and a substantially double-stranded stem by fragmenting a cDNA, enzymatically ligatingand enzymatically digesting the intermediate DNAmolecule with an endonuclease. | BergenBio (Bergen, Norway) | Lorens J, Micklem D | 12/24/2007 | 7/2/2009 |
US 20090156536 | An isolated small interfering RNA molecule comprisinga sense region and an antisense region that downregulates expression of a genetic disruption of p38 (AIMP2)-DX2 gene via RNAi. | Kim S | Choi JW, Kim S | 11/24/2004 | 6/18/2009 |
WO 2009073809 | A new RNAi agent for modulating the expression of atarget gene in treating, e.g., cancer, hepatitis C,dyslipidemia, diabetes, childhood asthma, malaria and multiple sclerosis, comprising a small interfering molecule conjugated to a carbohydrate. | Alnylam Pharmaceuticals (Cambridge, MA, USA) | Maier M, Manoharan M, Narayanannair JK, Rajeev KG | 12/4/2007 | 6/11/2009 |
CN 101455848 | Selecting a tumor metastasis–inhibiting gene using an RNAi library, comprising injecting a cell treated by RNAi into an immunodeficient mouse to form a lung tumor and expressing the tumor metastasis–inhibiting gene. | Huang H | Huang H, Luo R | 6/17/2009 | 1/5/2009 |
US 20060247428, JP 2008283975 | A method for synthesizing a double-stranded nucleic acid molecule, comprising a sense strand and an antisense strand by annealing two complementary strands under conditions suitable to obtain a double-stranded nucleic acid molecule. | Ribozyme Pharmaceuticals (Boulder, CO, USA), Sirna Therapeutics (San Francisco) | Beigelman L, Chen T, Chowrira B, Fosnaugh K, Haeberli P, Jamison S, Macejak D, McSwiggen J,Mokler V, Morrissey D, Pavco P, Thompson J, Usman N, Vaish N, Vargeese C, Wang W, Zinnen S | 2/20/2002 | 11/2/2006, 11/27/2008 |
